Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Current therapeutic anti-angiogenic biologics used for the treatment of pathological ocular angiogenesis such as in diabetic retinopathy and wet macular degeneration often lead to detrimental side effects due to their interference with normal blood vessel physiology. In this issue of EMBO Molecular Medicine, Michael et al report on a novel angiogenesis inhibitor with unique properties that allow for local inhibition of angiogenesis without detectable systemic side effects.

Original publication

DOI

10.1002/emmm.201404026

Type

Journal article

Journal

EMBO Mol Med

Publication Date

05/2014

Volume

6

Pages

577 - 579

Keywords

Biological Products, Eye, Humans, Neovascularization, Pathologic, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Vascular Endothelial Growth Factor A